[1]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
　LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
点击复制

脂蛋白a的治疗现状及研究新方向()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年6期
页码:
543
栏目:
综述
出版日期:
2021-06-25

文章信息/Info

Title:
The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a
作者:
林琳 李京秀 闫娜 刘丹阳 查理 金恩泽
 (哈尔滨医科大学附属第四医院心内科,黑龙江 哈尔滨 150000)
Author(s):
LIN Lin; LI Jingxiu; YAN Na; LIU Danyang; CHA Li; JIN Enze
 (Department of Cardiology,the Fourth Affiliated Hospital of Harbin Medical University,Harbin 150000,Heilongjiang,China)
关键词:
脂蛋白a; 反义治疗; 前蛋白转化酶枯草溶菌素9抑制剂; 血浆置换; 心血管疾病
Keywords:
Lipoprotein a; Antisense therapy; PCSK9 inhibitor; Lipoprotein apheresis; Cardiovascular diseases
DOI:
10.16806/j.cnki.issn.1004-3934.2021.06.016
摘要:
现有流行病学和临床证据证明，脂蛋白a水平是心血管疾病的独立危险因素，其作用机制主要是促进泡沫细胞形成，从而促进胆固醇在动脉粥样硬化斑块内的沉积。脂蛋白a由载脂蛋白B-100和载脂蛋白A共价结合而成，主要受遗传因素的影响。现基于对脂蛋白a的结构、病理生理功能以及和心血管疾病关系的认识，重点介绍前蛋白转化酶枯草溶菌素9抑制剂、ApoA和/或ApoB的反义治疗以及血浆置换等新兴疗法的应用，期待其在脂蛋白a的治疗中提供新的明确的线索。
Abstract:
The available epidemiological and clinical evidence proves that lipoprotein a[Lp(a)] level is an independent risk factor for the cardiovascular disease,and its mechanism is mainly to promote the formation of foam cells and then promote the deposition of cholesterin in atherosclerotic plaques. Lp(a) is formed by the covalent combination of apolipoprotein B-100 and apolipoprotein A. It is mainly influenced by genetic factors. Based on the understanding of the structure of Lp(a),the pathophysiological function of Lp(a),and the relationship between Lp(a) and cardiovascular disease,this article focuses on the application of PCSK9 inhibitors,antisense therapy of ApoA and/or ApoB,and lipoprotein apheresis and other emerging therapies. It can point out new and clear clues in the treatment of Lp(a)

参考文献/References:

[1]le Bras A. Lipoprotein(a) is an independent predictor of CVD[J]. Nat Rev Cardiol,2018,15(12):727.

[2]Wu MF,Xu KZ,Guo YG,et al. Lipoprotein(a) and atherosclerotic cardiovascular disease:current understanding and future perspectives[J]. Cardiovasc Drugs Ther,2019,33(6):739-748.

[3]Schmidt K,Noureen A,Kronenberg F,et al. Structure,function,and genetics of lipoprotein (a)[J]. J Lipid Res,2016,57(8):1339-1359.

[4]Tsimikas S. A test in context:lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.

[5]Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases[J]. Cardiovasc Drugs Ther,2016,30(1):87-100.

[6]Gencer B,Kronenberg F,Stroes ES,et al. Lipoprotein(a):the revenant[J]. Eur Heart J,2017,38(20):1553-1560.

[7]Boffa MB,Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease[J]. Nat Rev Cardiol,2019,16(5):305-318.

[8]Saleheen D,Haycock PC,Zhao W,et al. Apolipoprotein(a) isoform size,lipoprotein(a) concentration,and coronary artery disease:a mendelian randomisation analysis[J]. Lancet Diabetes Endocrinol,2017,5(7):524-533.

[9]Joshi PK,Pirastu N,Kentistou KA,et al. Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity[J]. Nat Commun,2017,8(1):910.

[10]Dai W,Long J,Cheng Y,et aL. Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease[J]. Sci Rep,2018,8(1):7726.

[11]Marcovina SM,Albers JJ. Lipoprotein (a) measurements for clinical application[J]. J Lipid Res,2016,57(4):526-537.

[12]Tsimikas S,Fazio S,Ferdinand KC,et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk?of?cardiovascular disease and aortic?stenosis[J]. J Am Coll Cardiol,2018,71(2):177-192.

[13]Cybulska B,K?osiewicz-Latoszek L,Penson PE,et al. What do we know about the role of lipoprotein(a) in atherogenesis 57?years after its discovery?[J]. Prog Cardiovasc Dis,2020,63(3):219-227.

[14]Lippi G,Favaloro EJ,Sanchis-Gomar F. Antisense lipoprotein(a) therapy:state-of-the-art and future perspectives[J]. Eur J Intern Med,2020,76:8-13.

[15]Awad K,Mikhailidis DP,Katsiki N,et al. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia:a systematic review and meta-analysis of randomized controlled trials[J]. Drugs,2018,78(4):453-462.

[16]Stulnig TM,Morozzi C,Reindl-Schwaighofer R,et al. Looking at Lp(a) and related cardiovascular risk:from scientific evidence and clinical practice[J]. Curr Atheroscler Rep,2019,21(10):37.

[17]Willeit P,Ridker PM,Nestel PJ,et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events:individual patient-data meta-analysis of statin outcome trials[J]. Lancet,2018,392(10155):1311-1320.

[18]Tsimikas S,Gordts PLSM,Nora C,et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J,2020,41(24):2275-2284.

[19]Wilson DP,Jacobson TA,Jones PH,et al. Use of Lipoprotein(a) in clinical practice:a biomarker whose time has come. A scientific statement from the National Lipid Association. [J]. J Clin Lipidol,2019,13(3):374-392.

[20]Gaudet D,Watts GF,Robinson JG,et al. Effect of alirocumab on lipoprotein(a) over ≥1.5?years(from the phase 3 ODYSSEY program)[J]. Am J Cardiol,2017,119(1):40-46.

[21]Reiner ?. Can Lp(a) lowering against background statin therapy really reduce cardiovascular risk?[J]. Curr Atheroscler Rep,2019,21(4):14.

[22]Watts GF,Chan DC,Somaratne R,et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics[J]. Eur Heart J,2018,39(27):2577-2585.

[23]Thompson G,Parhofer KG. Current role of lipoprotein apheresis[J]. Curr Atheroscler Rep,2019,21(7):26.

[24]Rosada A,Kassner U,Vogt A,et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?[J]. Artif Organs,2014,38(2):135- 141.

[25]Roeseler E,Julius U,Heigl F,et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease:prospective 5 years of follow-up and apolipoprotein(a) characterization[J]. Arterioscler Thromb Vasc Biol,2016,36(9):2019-2027.

[26]Stefanutti C,Julius U,Watts GF,et al. Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs[J]. J Clin Lipidol,2017,11(4):858-871.

[27]Fogacci F,Ferri N,Toth PP,et al. Efficacy and safety of mipomersen:a systematic review and meta-analysis of randomized clinical trials[J]. Drugs,2019,79(7):751-766.

[28]Stroes ES,van der Valk FM. A sense of excitement for a specific Lp(a)-lowering therapy[J]. Lancet,2015,386(10002):1427-1429.

相似文献/References:

[1]汤月霞 吴宗贵.脂蛋白a用于预测心血管疾病的争议[J].心血管病学进展,2019,(8):1158.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
　TANG Yuexia,WU Zonggui.Controversies about the Use of Lipoprotein() in Predicting Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1158.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
[2]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
　OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
[3]张小芳?张冬颖.RNA干扰疗法降低脂蛋白a的临床研究进展[J].心血管病学进展,2023,(7):622.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.011]
　ZHANG Xiaofang,ZHANG Dongying.Clinical Research of RNA Interference Therapy in Reducing Lipoprotein (a)[J].Advances in Cardiovascular Diseases,2023,(6):622.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.011]

更新日期/Last Update: 2021-07-23